Clinical trial NCT06965881: Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of Carbamazepine or Itraconazole With Radiprodil in Healthy Adults
Official title: A Phase 1, Open-label, 2-part Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of a CYP3A4 Inducer (Carbamazepine) or Inhibitor (Itraconazole), With Radiprodil in Healthy Adult Participants
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Tuberous Sclerosis Complex (TSC)
Focal Cortical Dysplasia
Other Neurological Disorders
Keywords: healthy adults
tuberous sclerosis
focal cortical dysplasia
Lead sponsor: GRIN Therapeutics, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Avance Clinical Pty Ltd.
First posted: 2025-05-11
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a Phase 1, open-label, 2-part study to evaluate the effect of multiple doses of oral carbamazepine or oral itraconazole on the plasma pharmacokinetic profile of radiprodil in healthy adult participants. In addition, the safety and tolerability of radiprodil given together with oral carbamazepine or itraconazole will be assessed.

Detailed description: This is an open label study conducted in healthy adult volunteers. The study will be conducted in 2 parallel parts. A total of 36 participants will be enrolled in the study (N=18 per Part).

Part A: will enrol 18 participants to receive multiple oral doses of the radiprodil in the range of 7.5mg to 30mg with oral carbamazepine.

Part B: will enrol 18 participants to receive multiple oral doses of radiprodil in the range of 7.5mg to 15mg with oral itraconazole.

Eligibility criteria: Inclusion Criteria:

* Healthy male and female adults between 18 and 55 years of age, inclusive, at Screening
* Body mass index (BMI) between 18 and 32 kg/m2 (inclusive) and weighs at least 50 kg at Screening
* Medically healthy in the opinion of the PI or delegate
* Female participants must be non-lactating and of non-child-bearing potential; or if child-bearing potential must agree to not to attempt to become pregnant or donate ova from signing consent until at least 90 days after the last dose of study drug and must agree to use adequate contraception
* Male participants must agree to not donate sperm from signing consent until at least 90 days after the last dose of study drug and must agree to use adequate contraception
* Have suitable venous access for blood sampling.
* Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions

Exclusion Criteria:

* Known hypersensitivity to the study drug or any of the study drug ingredients
* Genetic testing positive for HLA genotypes
* Has a history of severe allergic or anaphylactic reaction
* Has history of surgery in the past 90 days prior to Day 1
* Has a history of of risk factors for torsade de pointes or a known arrythmia
* Has a history of or positive serology for HIV, Hepatitis B or Hepatitis C virus at Screening.
* Has a history of suicide attempts or deliberate self-harm
* Use of cannabidiol (CBD) within 30days of Day -1
* Regular consumption of more than 10 standard alcoholic drinks/week and/or more than 4 standard alcoholic drinks on any one day
* Routine consumption of an average of more than five (5) 240 mL servings of coffee or other caffeinated beverages per day
* Use of tobacco-containing products and nicotine or nicotine containing products in the 2 months prior to Day -1
* Women of childbearing potential using oral, injected or implanted hormonal contraception
* Has any other condition or prior therapy that, in the opinion of the Investigator or delegate, may potentially compromise the safety or compliance of the participant, or may preclude the participant from successfully completing the study.

Other inclusion/exclusion eligibility criteria apply.

Primary outcomes:
measure: Part A: To assess the effect of oral carbamazepine on the maximum observed plasma concentration (Cmax) of oral dosing of radiprodil
timeFrame: Blood samples will be collected on Days 7 to 10 and 25 to 28.
measure: Part B: To assess the effect of oral itraconazole on the maximum plasma concentration (Cmax) of oral dosing of radiprodil
timeFrame: Blood samples will be collected Days 5 to 9 and 18 to 22.
measure: Part A: To asses the effect of oral carbamazepine on radiprodil area under the plasma concentration-time curve from 0 to last quantifiable concentration (AUClast)
timeFrame: Blood samples will be collected on Days 7 to 10 and 25 to 28.
measure: Part B: To asses the effect of oral itraconazole on the radiprodil area under the plasma concentration-time curve from 0 to last quantifiable concentration (AUClast)
timeFrame: Blood samples will be collected Days 5 to 9 and 18 to 22.
measure: Part A: To assess the effect of oral oral carbamazepine on the area under the plasma concentration-time curve to the end of dosing interval (AUCtau) of oral dosing of radiprodil
timeFrame: Blood samples will be collected on Days 7 to 10 and 25 to 28
measure: Part B: To assess the effect of oral itraconazole on the area under the plasma concentration-time curve to the end of dosing interval (AUCtau) of oral dosing of radiprodil
timeFrame: Blood samples will be collected Days 5 to 9 and 18 to 22
Secondary outcomes:
measure: Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (SAEs), TEAEs Leading to Discontinuation and Severity of TEAEs
timeFrame: From Screening to Day 30 and follow up visit 30 days post last dose
measure: Part A: To assess the area under the plasma concentration-time curve from 0 to last quantifiable concentration (AUClast) of carbamazepine and carbamazepine metabolites following oral dosing of carbamazepine alone and in the presence of radiprodil
timeFrame: Blood samples for plasma PK will be collected on Days 18 and 25.
measure: Part B: To assess the area under the plasma concentration-time curve from 0 to last quantifiable concentration (AUClast) of itraconazole following oral dosing of itraconazole alone and in the presence of radiprodil
timeFrame: Blood samples for plasma PK will be collected on Days 13 and 18.
measure: Part B: To assess the area under the plasma concentration-time curve to the end of dosing interval (AUCtau) of itraconazole following oral dosing of itraconazole alone and in the presence of radiprodil
timeFrame: Blood samples for plasma PK will be collected on Days 13 and 18.
measure: Part A: To assess the area under the plasma concentration-time curve to the end of dosing interval (AUCtau) of carbamazepine and carbamazepine metabolites following oral dosing of carbamazepine alone and in the presence of radiprodil
timeFrame: Blood samples for plasma PK will be collected on Days 18 and 25.
measure: Part A: To assess the time to maximum observed plasma concentration (Tmax) of carbamazepine and carbamazepine metabolites following oral dosing of carbamazepine alone and in the presence of radiprodil
timeFrame: Blood samples for plasma PK will be collected on Days 18 and 25.
measure: Part B: To assess the time to maximum observed plasma concentration (Tmax) of itraconazole following oral dosing of itraconazole alone and in the presence of radiprodil
timeFrame: Blood samples for plasma PK will be collected on Days 13 and 18.
measure: Part B: To assess the maximum observed plasma concentration (Cmax) of itraconazole following oral dosing of itraconazole alone and in the presence of radiprodil
timeFrame: Blood samples for plasma PK will be collected on Days 13 and 18.
measure: Part A: To assess the maximum observed plasma concentration (Cmax) of carbamazepine and carbamazepine metabolites following oral dosing of carbamazepine alone and in the presence of radiprodil
timeFrame: Blood samples for plasma PK will be collected on Days 18 and 25.
measure: Number of participants with abnormal laboratory test results
timeFrame: From Screening to Day 30 and follow up visit 30 days post last dose
measure: To assess the Columbia-Suicide Severity Rating Scale (C-SSRS) scores
timeFrame: From Screening to Day 30 and follow up visit 30 days post last dose
measure: 12-Lead ECG: Mean change from Baseline to End-of-Treatment in QT interval
timeFrame: From Screening to Day 30 and follow up visit 30 days post last dose
measure: 12-Lead ECG: Mean change from Baseline to End-of-Treatment in PR interval
timeFrame: From Screening to Day 30 and follow up visit 30 days post last dose
measure: 12-Lead ECG: Mean change from Baseline to End-of-Treatment in QRS interval
timeFrame: From Screening to Day 30 and follow up visit 30 days post last dose
Other outcomes:
Locations:
city: Brisbane
country: Australia
facility: Q-Pharm Pty Ltd
state: Queensland
city: Melbourne
country: Australia
facility: Nucleus Network Pty Ltd
state: Victoria
Study officials:
affiliation: GRIN Therapeutics, Inc.
name: Russell Chin
role: STUDY_DIRECTOR
References: